From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Combinations of Long-Acting Inhaled Agents for COPD

Adding formoterol to tiotropium yielded significant additional improvements.

ß-agonist and anticholinergic agents reduce symptoms in patients with chronic obstructive pulmonary disease (COPD). In this randomized, placebo-controlled, crossover study, European researchers examined the effect on lung function of combining the long-acting inhaled ß-agonist formoterol and the long-acting inhaled anticholinergic tiotropium (Spiriva). The study was funded by the maker of tiotropium.

Each of 95 patients with COPD received 2-week courses of tiotropium alone (once daily in the morning), tiotropium plus formoterol (both once daily in the morning), and tiotropium once daily plus formoterol twice daily. At baseline and at the end of each 2-week period, pulmonary function was measured repeatedly during a 24-hour period.

Mean forced vital capacity, FEV1, and inspiratory capacity increased from baseline levels with tiotropium alone. When once-daily formoterol was added to tiotropium, significant additional improvements in these measures were noted, mostly during the daytime. When formoterol was given twice daily, patients experienced additional incremental benefit overnight.

Comment: This study demonstrates that combined therapy with two long-acting bronchodilators confers a short-term improvement in pulmonary function in patients with COPD; once-daily or twice-daily formoterol, added to tiotropium, were both better than tiotropium alone. Two remaining questions are whether these changes in pulmonary function are sustained during long-term treatment, and whether they translate into improved symptoms.

— Allan S. Brett, MD

Published in Journal Watch General Medicine April 4, 2006

Citation(s):

van Noord JA et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006 Mar; 129:509-17.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2006. Massachusetts Medical Society. All rights reserved.